
Due to the huge demand for respiratory infection drugs, UPcare Group has provided its flagship products UPplus KBD Spray and UPplus A Capsules to around 100 pharmacies in multiple states of Australia. Our sales reps will visit more stores in the upcoming months.

As a marketed drug approved in Australia, UPplus natural products are very safe and extremely helpful for the early protection of various respiratory infections before they get worsen. Large number of customers who have used these products provided feedbacks that they like them, and as of the time of writing, there virtually is no similar drug substitute with multi-target functions and purely natural ingredients in the market.
Although the world's major pharmacy giants are still working hard to develop prescription drugs to prevent COVID19, the long process of human trials, the safety of chemical drugs, and the efficacy of these drugs also needs longer time to tell, especially when the virus often mutates.

(Both UPplus KBD Spray and A Capsules Being Sold in Pharamcies)
UPcare Group has adopted a "two-pronged" smart product development strategy for both non-prescription drugs (compelmentary medicine agaisnt respiratory infections) and prescription drugs (directly against SARS-CoV-2) . For prescription drugs, UPcare is currently raising funds for clinical trials, and the registration of prescription drugs will usually take about 50-100 million US dollars and several months to collect the final efficacy data of the drug against the SARS-CoV-2 virus. However, because UPcare's UPplus products have been granted license by authorities in Australia and USA to be safe to use, they are purely manufactured from natural herbal ingredients, and gained exceptional results from the preclinical test agaisnt the SARS-CoV-2 virus by Peter Doherty Institute, so it is legal and wise to put them on the market first to help people protect the health of the respiratory system. The extra protection actually have already helped many people to relieve and recover sooner.

We strongly urge the governments, enterprises and the public to do their best to equip with UPplus products for superior respiratory protection. Ultimately, early prevention or extra protection is the key to alleviating the possible problems and costly consequences.

√√√ Order Online now:
or
√√√ visit a local pharmacy store:

About UPcare Group
UPCare Group Pty Ltd global biopharmaceutical company and a world leader in the development of pharmaceutical and medical products based on natural botanic combinations called UPplus® with focuses on COVID-19. UPcare has developed UPplus KBD Spray™ (an antiviral oral spray) and UPplus A Capsules™ (an antiviral capsule) for COVID-19 and other respiratory infections, which are complementary to vaccines and other preventative measures such as PPE. Both UPplus® products are approved by Australia and USA government authorities and allowed for sales and export.
As a leading company in the botanic based drug delivery, UPcare’s proprietary drug delivery platform Apex Biotech Research, which has been collaborating with the prestigious Monash Univeristy is being used to screening compounds, improve pharmaceuticals, to reduce toxicities and enhance their performance.
Comments